Stay updated on REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page
- Check3 days agoChange DetectedResults for NCT03515629 have been posted, including updates to primary and secondary outcomes and the overall study status. The primary endpoint PFS is noted as not assessed due to insufficient data, with other outcomes outlined.SummaryDifference0.4%

- Check10 days agoNo Change Detected
- Check32 days agoChange DetectedMajor update: operating-status notice and new version v3.2.0; old v3.1.0 reference removed.SummaryDifference4%

- Check39 days agoChange DetectedUpgrade applied: version updated from v3.0.2 to v3.1.0. No other substantive content changes detected.SummaryDifference0.1%

- Check53 days agoChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1, and the 'Back to Top' element was removed as a minor UI cleanup.SummaryDifference0.2%

- Check60 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%

- Check67 days agoChange DetectedThe web page has updated its facility name and location details, specifically adding St. Petersburg, Florida, and the drug names cemiplimab and pembrolizumab, while removing previous location and drug references.SummaryDifference4%

Stay in the know with updates to REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REGN2810 Combo vs Pembrolizumab in Lung Cancer Clinical Trial page.